Evidence map›Paper›PMID 40786815›Full record

ReviewJournal of the Canadian Association of Gastroenterology2024

Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.

Fouad Jaber, George Cholankeril, Hashem B El-Serag

Abstract readReview
In one paragraph

Review in Journal of the Canadian Association of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fouad JaberDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, United States.
George CholankerilDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, United States.
Hashem B El-SeragDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, United States.ORCID https://orcid.org/0000-0001-5964-7579

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
Prevention of Hepatocellular Carcinoma Related to Metabolic SyndromeP01CA263025 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Christopher I. Amos · 2022 to 2026
$8.9M
Risk Stratification for and Early Detection of Liver CancerU01CA230997 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jagpreet Chhatwal, Hashem B El-Serag · 2018 to 2026
$6.4M
NCI NIH HHS P01 CA263025NCI NIH HHS U01 CA230997NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

The contemporary epidemiology of hepatocellular carcinoma (HCC) shows a shift in the main etiological risk factors from less common but highly virulent (eg, hepatitis C and B) to more common but weak risk factors (eg, alcohol and metabolic syndrome). Therefore, we are in a seemingly paradoxical state of declining overall incidence rates of HCC-related to improved prevention and treatment of viral hepatitis but burgeoning number of people at an elevated risk of HCC. Several geographic regions have reported an increase in HCC attributable to alcoholic liver disease and metabolic dysfunction associated with steatotic liver disease (MASLD). The importance of risk stratification is increasing to allow for targeted prevention and early detection of HCC. Most risk factors predispose HCC through the formation of cirrhosis, which has served as the main risk stratifying factor. However, this scheme is showing cracks at both ends of the spectrum. On one hand, the risk of developing HCC varies widely among patients with contemporary advanced fibrosis or cirrhosis, and on the other hand up to one-third of MASLD-related HCC occurs among patients with no clear evidence of cirrhosis. The use of multidimensional (eg, clinical, epidemiological, and biochemical) predictive algorithms may improve risk stratification efforts. The shift in HCC risk factors also further heightened the importance and limitations of current surveillance practices (eg, reduced performance of ultrasound in MASLD). Therefore, exploring advanced imaging methods, new biomarkers but also existing combinations of biomarkers augmented by clinical factors for HCC early detection is crucial.

Indexed as

biomarkersfatty liverfibrosisliver cancermetabolic dysfunctionNAFLDsurveillance

Identifiers

PMID40786815
PMCPMC11477987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.